FDA核准Polidocanol用於治療小型靜脈曲張, 指1毫米以下的蜘蛛靜脈跟1-3毫米間的網狀靜脈
By Emma Hitt, PhD
Medscape Medical News
March 31, 2010 — The US Food and Drug Administration (FDA) has approved polidocanol injection (Asclera, Chemische Fabrik Kreussler & Co) for the treatment of small varicose veins.
Specifically, polidocanol is approved to close spider veins (<1 mm in diameter) and reticular veins (1 - 3 mm in diameter), according to the FDA press release issued on Monday.
"Asclera is indicated for the treatment of small types of varicose veins when the aim of treatment is to improve appearance," noted Norman Stockbridge, MD, PhD, from the Center for Drug Evaluation and Research at the FDA, in the written release.
Polidocanol creates fibrosis within the cell lining of blood vessels, causing them to collapse; the vein is then eventually replaced by other types of tissue.
Adverse reactions to polidocanol include leakage, hematoma, bruising, irritation, discoloration, and pain at the injection site.
 　
　 　　Polidocanol會使血管細胞內層纖維化，使它們崩解；最後由其他類型組織取代該靜脈。
　　
　　與polidocanol有關的副作用包括外滲、血腫、刺激、變色與注射部位疼痛。

polidocanol
polidpcanol0.5.jpg 

這下子台灣要專案引進這個更沒有併發症的藥物又將是指日可待了